2160 Stock Overview
MicroPort CardioFlow Medtech Corporation, a medical device company, researches, develops, and commercializes transcatheter and surgical solutions for structural heart diseases in the People’s Republic of China.
MicroPort CardioFlow Medtech Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$3.43|
|52 Week High||HK$16.80|
|52 Week Low||HK$2.05|
|1 Month Change||60.28%|
|3 Month Change||32.95%|
|1 Year Change||-79.19%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-81.77%|
Recent News & Updates
Analysts Just Made A Major Revision To Their MicroPort CardioFlow Medtech Corporation (HKG:2160) Revenue Forecasts
Market forces rained on the parade of MicroPort CardioFlow Medtech Corporation ( HKG:2160 ) shareholders today, when...
|2160||HK Medical Equipment||HK Market|
Return vs Industry: 2160 underperformed the Hong Kong Medical Equipment industry which returned -60.3% over the past year.
Return vs Market: 2160 underperformed the Hong Kong Market which returned -23.3% over the past year.
|2160 Average Weekly Movement||10.5%|
|Medical Equipment Industry Average Movement||8.4%|
|Market Average Movement||7.0%|
|10% most volatile stocks in HK Market||13.8%|
|10% least volatile stocks in HK Market||3.3%|
Stable Share Price: 2160 is more volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: 2160's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
MicroPort CardioFlow Medtech Corporation, a medical device company, researches, develops, and commercializes transcatheter and surgical solutions for structural heart diseases in the People’s Republic of China. It offers Vitaflow Aortic Valve System, Alwide Balloon Catheter, and Alpass Introducer Set to target aortic, mitral, tricuspid, and surgical valves, as well as procedural accessories. The company was founded in 2010 and is headquartered in Shanghai, China.
MicroPort CardioFlow Medtech Fundamentals Summary
|2160 fundamental statistics|
Is 2160 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|2160 income statement (TTM)|
|Cost of Revenue||CN¥82.11m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.076|
|Net Profit Margin||-91.26%|
How did 2160 perform over the long term?See historical performance and comparison
Is 2160 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2160?
Other financial metrics that can be useful for relative valuation.
|What is 2160's n/a Ratio?|
Price to Sales Ratio vs Peers
How does 2160's PS Ratio compare to its peers?
|2160 PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
Price-To-Sales vs Peers: 2160 is expensive based on its Price-To-Sales Ratio (35x) compared to the peer average (14x).
Price to Earnings Ratio vs Industry
How does 2160's PE Ratio compare vs other companies in the Hong Kong Medical Equipment Industry?
Price-To-Sales vs Industry: 2160 is expensive based on its Price-To-Sales Ratio (35x) compared to the Hong Kong Medical Equipment industry average (6.2x)
Price to Sales Ratio vs Fair Ratio
What is 2160's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||35x|
|Fair PS Ratio||10.5x|
Price-To-Sales vs Fair Ratio: 2160 is expensive based on its Price-To-Sales Ratio (35x) compared to the estimated Fair Price-To-Sales Ratio (10.5x).
Share Price vs Fair Value
What is the Fair Price of 2160 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 2160 (HK$3.43) is trading below our estimate of fair value (HK$13.35)
Significantly Below Fair Value: 2160 is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 2160's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is MicroPort CardioFlow Medtech forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2160 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 2160 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 2160 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 2160's revenue (36.7% per year) is forecast to grow faster than the Hong Kong market (10.2% per year).
High Growth Revenue: 2160's revenue (36.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2160 is forecast to be unprofitable in 3 years.
Discover growth companies
How has MicroPort CardioFlow Medtech performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Last years earnings growth
Earnings and Revenue History
Quality Earnings: 2160 is currently unprofitable.
Growing Profit Margin: 2160 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 2160's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 2160's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2160 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (35.4%).
Return on Equity
High ROE: 2160 has a negative Return on Equity (-5.92%), as it is currently unprofitable.
Discover strong past performing companies
How is MicroPort CardioFlow Medtech's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: 2160's short term assets (CN¥2.6B) exceed its short term liabilities (CN¥164.4M).
Long Term Liabilities: 2160's short term assets (CN¥2.6B) exceed its long term liabilities (CN¥101.1M).
Debt to Equity History and Analysis
Debt Level: 2160 is debt free.
Reducing Debt: 2160 had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 2160 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 2160 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
What is MicroPort CardioFlow Medtech current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 2160's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 2160's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 2160's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 2160's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 2160 has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Guoming Chen (36 yo)
Mr. Guoming Chen serves as Executive Director and President of MicroPort CardioFlow Medtech Corporation since September 29, 2020. Mr. Chen serves as a Director and General Manager of MP CardioFlow on Septe...
Experienced Management: 2160's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Experienced Board: 2160's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
MicroPort CardioFlow Medtech Corporation's employee growth, exchange listings and data sources
- Name: MicroPort CardioFlow Medtech Corporation
- Ticker: 2160
- Exchange: SEHK
- Founded: 2010
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: HK$8.252b
- Shares outstanding: 2.41b
- Website: https://www.cardioflowmedtech.com
Number of Employees
- MicroPort CardioFlow Medtech Corporation
- Zhangjiang Hi-Tech Park
- No. 1601 Zhangdong Road
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/25 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.